The main challenge in chemical male contraceptives is targeting spermatogenesis without systemic side effects
the verdict
SUPPORTED
the evidence backs this
confidence 81/100
Recent advancements in non-hormonal and hormonal male contraceptives focus heavily on precisely targeting spermatogenesis and sperm maturation while avoiding systemic side effects.
Evidence for · 4
Targeting the retinoid signaling pathway with YCT-529 for effective and reversible oral contraception in mice and primates.
2025 · cited by 9
Studies on YCT-529 demonstrate successful targeting of spermatogenic pathways with minimal adverse side effects.
See more details
More for · 3
Novel Genes of the Male Reproductive System: Potential Roles in Male Reproduction and as Non-hormonal Male Contraceptive Targets.
2024 · cited by 3
Reviews on novel non-hormonal targets emphasize the pursuit of specific, reversible inhibition without systemic toxicity.
Meiotic prophase I disruption as a strategy for nonhormonal male contraception using small-molecule inhibitor JQ1.
2026 · cited by 1
Research on the small-molecule inhibitor JQ1 shows that meiotic prophase I can be targeted to disrupt spermatogenesis transiently without lasting reproductive or systemic defects.
Male Hormonal Contraception-Current Stage of Knowledge.
2025 · cited by 1
Investigations into hormonal candidates like DMAU and 11beta-MNTDC focus on achieving effective spermatogenesis suppression while minimizing side effects.